Anne-Marie Lefrançois-Martinez |
|
|
|
Université Blaise Pascal - Clermont-Ferrand II
·
UFR Sciences et Technologies
|
Publications (21) View all
-
Article: Analysis of the Role of Igf2 in Adrenal Tumour Development in Transgenic Mouse Models
Coralie Drelon, Annabel Berthon, Bruno Ragazzon, Fré Dé Rique Tissier, Roberto Bandiera, Isabelle Sahut-Barnola, Cyrille De Joussineau, Marie Batisse-Lignier, Anne-Marie Lefrançois-Martinez, Jé Rô Me Bertherat, Antoine Martinez, Pierre Val[show abstract] [hide abstract]
ABSTRACT: Adrenal cortical carcinomas (ACC) are rare but aggressive tumours associated with poor prognosis. The two most frequent alterations in ACC in patients are overexpression of the growth factor IGF2 and constitutive activation of Wnt/b-catenin signalling. Using a transgenic mouse model, we have previously shown that constitutive active b-catenin is a bona fide adrenal oncogene. However, although all these mice developed benign adrenal hyperplasia, malignant progression was infrequent, suggesting that secondary genetic events were required for aggressive tumour development. In the present paper, we have tested IGF2 oncogenic properties by developing two distinct transgenic mouse models of Igf2 overexpression in the adrenal cortex. Our analysis shows that despite overexpression levels ranging from 7 (basal) to 87 (ACTH-induced) fold, Igf2 has no tumour initiating potential in the adrenal cortex. However, it induces aberrant accumulation of Gli1 and Pod1-positive progenitor cells, in a hedgehog-independent manner. We have also tested the hypothesis that Igf2 may cooperate with Wnt signalling by mating Igf2 overexpressing lines with mice that express constitutive active b-catenin in the adrenal cortex. We show that the combination of both alterations has no effect on tumour phenotype at stages when b-catenin-induced tumours are benign. However, there is a mild promoting effect at later stages, characterised by increased Weiss score and proliferation. Formation of malignant tumours is nonetheless a rare event, even when Igf2 expression is further increased by ACTH treatment. Altogether these experiments suggest that the growth factor IGF2 is a mild contributor to malignant adrenocortical tumourigenesis.PLoS ONE 08/2012; 7(8):e44171. · 4.09 Impact Factor -
Article: Depressed levels of prostaglandin f2α in mice lacking akr1b7 increase Basal adiposity and predispose to diet-induced obesity.
Fanny E Volat, Jean-Christophe Pointud, Emilie Pastel, Béatrice Morio, Benoit Sion, Ghislaine Hamard, Michel Guichardant, Romain Colas, Anne-Marie Lefrançois-Martinez, Antoine Martinez[show abstract] [hide abstract]
ABSTRACT: Negative regulators of white adipose tissue (WAT) expansion are poorly documented in vivo. Prostaglandin F(2α) (PGF(2α)) is a potent antiadipogenic factor in cultured preadipocytes, but evidence for its involvement in physiological context is lacking. We previously reported that Akr1b7, an aldo-keto reductase enriched in adipose stromal vascular fraction but absent from mature adipocytes, has antiadipogenic properties possibly supported by PGF(2α) synthase activity. To test whether lack of Akr1b7 could influence WAT homeostasis in vivo, we generated Akr1b7(-/-) mice in 129/Sv background. Akr1b7(-/-) mice displayed excessive basal adiposity resulting from adipocyte hyperplasia/hypertrophy and exhibited greater sensitivity to diet-induced obesity. Following adipose enlargement and irrespective of the diet, they developed liver steatosis and progressive insulin resistance. Akr1b7 loss was associated with decreased PGF(2α) WAT contents. Cloprostenol (PGF(2α) agonist) administration to Akr1b7(-/-) mice normalized WAT expansion by affecting both de novo adipocyte differentiation and size. Treatment of 3T3-L1 adipocytes and Akr1b7(-/-) mice with cloprostenol suggested that decreased adipocyte size resulted from inhibition of lipogenic gene expression. Hence, Akr1b7 is a major regulator of WAT development through at least two PGF(2α)-dependent mechanisms: inhibition of adipogenesis and lipogenesis. These findings provide molecular rationale to explore the status of aldo-keto reductases in dysregulations of adipose tissue homeostasis.Diabetes 07/2012; 61(11):2796-806. · 8.29 Impact Factor -
SourceAvailable from: PubMed Central
Article: Aldo-Keto Reductases 1B in Endocrinology and Metabolism.
Emilie Pastel, Jean-Christophe Pointud, Fanny Volat, Antoine Martinez, Anne-Marie Lefrançois-Martinez[show abstract] [hide abstract]
ABSTRACT: The aldose reductase (AR; human AKR1B1/mouse Akr1b3) has been the focus of many research because of its role in diabetic complications. The starting point of these alterations is the massive entry of glucose in polyol pathway where it is converted into sorbitol by this enzyme. However, the issue of AR function in non-diabetic condition remains unresolved. AR-like enzymes (AKR1B10, Akr1b7, and Akr1b8) are highly related isoforms often co-expressed with bona fide AR, making functional analysis of one or the other isoform a challenging task. AKR1B/Akr1b members share at least 65% protein identity and the general ability to reduce many redundant substrates such as aldehydes provided from lipid peroxidation, steroids and their by-products, and xenobiotics in vitro. Based on these properties, AKR1B/Akr1b are generally considered as detoxifying enzymes. Considering that divergences should be more informative than similarities to help understanding their physiological functions, we chose to review specific hallmarks of each human/mouse isoforms by focusing on tissue distribution and specific mechanisms of gene regulation. Indeed, although the AR shows ubiquitous expression, AR-like proteins exhibit tissue-specific patterns of expression. We focused on three organs where certain isoforms are enriched, the adrenal gland, enterohepatic, and adipose tissues and tried to connect recent enzymatic and regulation data with endocrine and metabolic functions of these organs. We presented recent mouse models showing unsuspected physiological functions in the regulation of glucido-lipidic metabolism and adipose tissue homeostasis. Beyond the widely accepted idea that AKR1B/Akr1b are detoxification enzymes, these recent reports provide growing evidences that they are able to modify or generate signal molecules. This conceptually shifts this class of enzymes from unenviable status of scavenger to upper class of messengers.Frontiers in pharmacology. 01/2012; 3:148. -
SourceAvailable from: Cyrille de Joussineau
Article: Cushing's syndrome and fetal features resurgence in adrenal cortex-specific Prkar1a knockout mice.
Isabelle Sahut-Barnola, Cyrille de Joussineau, Pierre Val, Sarah Lambert-Langlais, Christelle Damon, Anne-Marie Lefrançois-Martinez, Jean-Christophe Pointud, Geoffroy Marceau, Vincent Sapin, Frédérique Tissier, Bruno Ragazzon, Jérôme Bertherat, Lawrence S Kirschner, Constantine A Stratakis, Antoine Martinez[show abstract] [hide abstract]
ABSTRACT: Carney complex (CNC) is an inherited neoplasia syndrome with endocrine overactivity. Its most frequent endocrine manifestation is primary pigmented nodular adrenocortical disease (PPNAD), a bilateral adrenocortical hyperplasia causing pituitary-independent Cushing's syndrome. Inactivating mutations in PRKAR1A, a gene encoding the type 1 alpha-regulatory subunit (R1alpha) of the cAMP-dependent protein kinase (PKA) have been found in 80% of CNC patients with Cushing's syndrome. To demonstrate the implication of R1alpha loss in the initiation and development of PPNAD, we generated mice lacking Prkar1a specifically in the adrenal cortex (AdKO). AdKO mice develop pituitary-independent Cushing's syndrome with increased PKA activity. This leads to autonomous steroidogenic genes expression and deregulated adreno-cortical cells differentiation, increased proliferation and resistance to apoptosis. Unexpectedly, R1alpha loss results in improper maintenance and centrifugal expansion of cortisol-producing fetal adrenocortical cells with concomitant regression of adult cortex. Our data provide the first in vivo evidence that loss of R1alpha is sufficient to induce autonomous adrenal hyper-activity and bilateral hyperplasia, both observed in human PPNAD. Furthermore, this model demonstrates that deregulated PKA activity favors the emergence of a new cell population potentially arising from the fetal adrenal, giving new insight into the mechanisms leading to PPNAD.PLoS Genetics 06/2010; 6(6):e1000980. · 8.69 Impact Factor -
Article: Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development.
Annabel Berthon, Isabelle Sahut-Barnola, Sarah Lambert-Langlais, Cyrille de Joussineau, Christelle Damon-Soubeyrand, Estelle Louiset, Mark M Taketo, Frédérique Tissier, Jérôme Bertherat, Anne-Marie Lefrançois-Martinez, Antoine Martinez, Pierre Val[show abstract] [hide abstract]
ABSTRACT: Adrenocortical carcinoma is a rare but aggressive cancer with unknown aetiology. Constitutive activation of beta-catenin is the most frequent alteration in benign and malignant adrenocortical tumours in patients. Here, we show that constitutive activation of beta-catenin in the adrenal cortex of transgenic mice resulted in progressive steroidogenic and undifferentiated spindle-shaped cells hyperplasia as well as dysplasia of the cortex and medulla. Over a 17 months time course, transgenic adrenals developed malignant characteristics such as uncontrolled neovascularization and loco-regional metastatic invasion. These oncogenic events were accompanied by ectopic differentiation of glomerulosa at the expense of fasciculata cells, which caused primary hyperaldosteronism. Altogether these observations demonstrate that constitutively active beta-catenin is an adrenal oncogene which triggers benign aldosterone-secreting tumour development and promotes malignancy.Human Molecular Genetics 04/2010; 19(8):1561-76. · 7.64 Impact Factor